Editorial Policy: How We Write About NAD+

Illustration of an editorial policy document with a magnifying glass and the points: FDA and NIH sources, clear about evidence, corrected when needed — How NADMedics writes and sources health information.

1. Our purpose

We publish clear, accurate information about NAD+ therapy so you can make informed decisions with a licensed provider. Our pages are general education, not a substitute for medical advice.

2. How we write

Plain language. We explain medical terms and avoid hype.
Honest about evidence. We separate what is known, what is still being studied and what isn't proven.
Clear about regulation. We state plainly that NAD+ has no FDA-approved use and that compounded NAD+ is not FDA-approved.

3. Sourcing standards

We rely on regulators such as the FDA, peer-reviewed research indexed in PubMed and established medical references. Sources are listed on each treatment page so you can check them yourself.

4. Review and updates

Treatment pages show the date they were last reviewed. We revisit content when research, regulations or our services change.

5. Corrections

Spotted something wrong or out of date? Email team@nadmedics.org and we'll review it and correct the page if needed.

Official resources

Government and independent resources related to this policy:

Human Drug Compounding (U.S. Food and Drug Administration)
Niacin: Health Professional Fact Sheet (NIH Office of Dietary Supplements)
Covarrubias et al. NAD+ metabolism and its roles in cellular processes during ageing (2021) (NIH PubMed Central)
NAD+ therapy in age-related degenerative disorders: a benefit/risk analysis (2020) (NIH PubMed)
MedWatch: The FDA Safety Information and Adverse Event Reporting Program (U.S. Food and Drug Administration)